The 3rd International Electronic Conference on Biomedicines
The 3rd International Electronic Conference on Biomedicines
Part of the International Electronic Conference on Biomedicines series
Event's Timezone: Central European Summer TimeNeurodegeneration, Neuromodulation, Therapeutic Targets, Precision Medicine, Infectious Diseases, Cardiovascular Diseases, Metabolic Diseases, Cancer, Biomedicine
The registration for ECB 2025 is now closed.
The ECB 2025 conference program is now online.
We’re pleased to announce that the overview program is now available online. Please find the details below:
Overview Program:
https://sciforum.net/event/ECB2025?section=#Program_Overview
Daily Programs:
• Day 1: https://sciforum.net/event/ECB2025?section=#program_day1
• Day 2: https://sciforum.net/event/ECB2025?section=#program_day2
• Day 3: https://sciforum.net/event/ECB2025?section=#program_day3
• Day 4: https://sciforum.net/event/ECB2025?section=#program_day4
We look forward to your participation in the upcoming ECB2025 LIVE sessions!
Welcome from the Chairs
Dear colleagues,
It is a great pleasure to welcome you to the 3rd International Electronic Conference on Biomedicines (ECB 2025), which will be held from 12 to 15 May 2025. This electronic conference will be held online at https://sciforum.net/event/ECB2025.
The goal of this conference is to enable scientists to present their latest research in the field of biomedicines and engage in discussions with the scientific community worldwide. Recent advances in biomedical research have provided an advanced insight into the biological background of human disease, setting the groundwork for the development of new therapeutic strategies. This conference aims to connect scientists working on this field of research from across the globe, allowing them to exchange ideas on the discovery and characterization of new therapeutic targets in the era of precise medicine.
The agenda of the conference includes, but is not limited to, the following topics:
S1. Insulin Resistance or Hyperinsulinemia
S2. Immunotherapy and Adverse Effects
S3. Tumor Microenvironment
S4. Immune System, Tumor Immunology and Autoimmune Disease
S5. Biomedicine in Cardiovascular Diseases
S6. Diabetes, Obesity and Metabolic Diseases
S7. Gene Therapy and Gene Editing
S8. Rare Diseases
S9. Molecular Mechanisms of Neurodegeneration
The ECB 2025 will be an online-only event, enabling scientists from all over the world to participate, with a small registration fee, but with no requirement for travel or related expenses. The electronic form of the conference provides a platform for rapid and direct exchanges regarding the latest research findings and novel ideas.
All participants are encouraged to submit an extended full manuscript for potential publication in the Biomedicines journal (ISSN: 2227-9059), with a 20% discount on the publication fee. All submitted papers will undergo MDPI’s standard peer-review procedure.
We look forward to receiving your contributions to this scientific event, and we would like to thank you in advance for your support.
Conference chairs
Prof. Dr. Felipe Fregni,
Prof. Dr. Allan Stensballe,
Prof. Dr. Georgia Levidou,
Prof. Dr. Serafino Fazio
Follow the conference organizer on Social Media
Program Overview
| 12 May 2025 9:00–11:30 CEST |
13 May 2025 9:00–12:00 CEST |
14 May 2025 9:00–11:30 CEST |
15 May 2025 9:00–10:00 CEST |
| Session 2. Immunotherapy and Adverse Effects Session 7. Gene Therapy and Gene Editing |
Session 5. Biomedicine in Cardiovascular Diseases | Session 9. Molecular Mechanisms of Neurodegeneration | Flash Poster Session |
| 12 May 2025 13:00–15:30 CEST |
13 May 2025 13:00–15:30 CEST |
14 May 2025 13:00–16:00 CEST |
|
| Session 4. Immune System, Tumor Immunology and Autoimmune Disease | Session 3. Tumor Microenvironment | Session 1. Insulin Resistance or Hyperinsulinemia Session 6. Diabetes, Obesity and Metabolic Diseases Session 8. Rare Diseases |
ECB 2025 Program (DAY1)
Session 2. Immunotherapy and Adverse Effects
Session 7. Gene Therapy and Gene Editing
Date: 12 May 2025 (Monday)
Time: 9:00 CEST, Basel | 03:00 EDT, New York | 15:00 CST Asia, Beijing
Session 4. Immune System, Tumor Immunology and Autoimmune Disease
Date: 12 May 2025 (Monday)
Time: 13:00 CEST, Basel | 07:00 EDT, New York | 19:00 CST Asia, Beijing
ECB 2025 Program (DAY2)
Session 5. Biomedicine in Cardiovascular Diseases
Date: 13 May 2025 (Tuesday)
Time: 09:00 CEST, Basel | 03:00 EDT, New York | 03:00 CST Asia, Beijing
Session 3. Tumor Microenvironment
Date: 13 May 2025 (Tuesday)
Time: 13:00 CEST, Basel | 07:00 EDT, New York | 19:00 CST Asia, Beijing
| Time in CEST | Speaker | Title |
| 13:00–13:10 |
Prof. Dr. Georgia Levidou |
Welcome from the Session Chair S3. Tumor Microenvironment |
| 13:10–13:40 |
Prof. Dr. Michele Ammendola |
The Tumor Microenvironment in Gastrointestinal Cancers Surgically Treated |
| 13:40–13:55 | Karolina Beton-Mysur | Can Statins Transform Human Colon Cell Behavior? Unveiling the Insights from Raman Imaging and AFM. |
| 13:55–14:10 | Aditya Vayalapalli | DAVID Analysis Suggests Novel Chemoresistance Pathways in Ovarian Cancer |
| 14:10–14:25 | Domenico Damiani | Translational Clinical Feasibility of Recent Advances in Liquid Biopsy Technology in Effusion Fluids: Preliminary Results |
| 14:25–14:40 | EMİNE AKPINAR | Quantum Artificial Intelligence in Tumor Classification: An Innovative Method for Biomedical Data Analysis |
| 14:40–14:55 | Irina Valerievna Pronina | Alterations in the Expression of a Group of Genes Associated with the Epithelial-Mesenchymal Transition in Lung Cancer: a Pilot Study |
ECB 2025 Program (DAY3)
Session 9. Molecular Mechanisms of Neurodegeneration
Date: 14 May 2025 (Wednesday)
Time: 9:00 CEST, Basel | 03:00 EDT, New York | 03:00 CST Asia, Beijing
| Time in CEST | Speaker | Title |
| 9:00–9:10 | Prof. Masaru Tanaka Session Chair |
Welcome from the Session Chair |
| 9:10–9:35 | Dr. Mario García Domínguez Invited Speaker |
A Comprehensive Analysis of Fibromyalgia and the Role of the Endogenous Opioid System |
| 9:35–9:50 | ISHANT DIWAKAR DAHAKE | Nanomechanics and Conformational Polymorphism in Neurotoxic Proteins: Understanding Amyloidogenic Neurodegenerative Diseases |
| 9:50–10:05 | Nivedita Adhikari | Development and Assessment of a Candesartan-loaded Bilosomal In Situ gel for Targeted Nose-to-Brain Delivery |
| 10:05–10:20 | Elika Valehi | Advancement in Liposomal Technology with Various Active Compounds for Neurodegenerative Disease Treatment |
| 10:20–10:35 | David Joshua Ferguson | Design of Partial Agonists of ADAMTS Metalloproteinases as Therapeutics for Neurodegenerative Diseases |
| 10:35–10:50 | Hugo F. Costa-Almeida | Discovery of Potent Positive Allosteric Modulators of the D2 Receptors through Conjugation of Melanostatin Neuropeptide with Amantadine |
| 10:50–11:05 | Ezgi Nur YUKSEK | Neuroprotective Effects of the Flowers of Camellia Japonica Var. Hagoromo: A Potential Candidate for Neurodegenerative Disease Treatment |
| 11:05–11:20 | Beatriz L. Pires-Lima | Discovery of Potent Melanostatin-Based Positive Allosteric Modulators of the Dopamine D2 Receptors Using Heteroaromatic Scaffolds |
| 11:20–11:35 | Roxana Gheorghita | The impact of persistent neurological manifestations in Long COVID-19 syndrome on daily life quality |
S1. Insulin Resistance or Hyperinsulinemia
S6. Diabetes, Obesity and Metabolic Diseases
Date: 14 May 2025 (Wednesday)
Time: 13:00 CEST, Basel | 07:00 EDT, New York | 19:00 CST Asia, Beijing
S8. Rare Diseases
Date: 14 May 2025 (Wednesday)
Time: 14:35 CEST, Basel | 07:35 EDT, New York | 19:35 CST Asia, Beijing
ECB 2025 Program (DAY4)
Flash Poster Session
Date: 15 May 2025 (Thursday)
Time: 9:00 CEST, Basel | 03:00 EDT, New York | 03:00 CST Asia, Beijing
| Time in CEST | Speaker | Title |
| 9:00–9:10 | Event Host | Opening: Welcome from the Event Host |
| 9:10–9:15 | Marlene Santos | Exploring the Role of Oral Antidiabetic Medications as Adjuncts in Depression Treatment |
| 9:15–9:20 | Yassine Mouniane | Biomedical Approaches Involving the Carob Tree (Ceratonia siliqua L.) for the Management of Obesity and Diabetes |
| 9:20–9:25 | MAUL SHREE | Bioinformatics Analysis of Retatrutide on Insulin Resistance Pathway Leading to T2DM |
| 9:25–9:30 | Ana Olívia Serra Jorge | Withaferin A from Withania somnifera: A Plant-Based Immunomodulator to Reduce Adverse Effects of Cancer Immunotherapy |
| 9:30–9:35 | Kunpeng Wang | Comprehensive Transcriptomic Profiling and ceRNA Network Analysis Reveal Hub Genes and Therapeutic Targets in HPV-Positive Head and Neck Squamous-Cell Carcinoma |
| 9:35–9:40 | Veronica Filetti | Evaluation of ncRNA Expression Levels in the Lung after Environmental Exposure to Fluoro-Edenite Fibers |
| 9:40–9:45 | Parsa Mahmood Dar | Exploring the Advances in Plaque Psoriasis Research: A Scientometric Analysis and Visualization (2000-2025) |
| 9:45–9:50 | Alexandru Vasile Rusu | Stabilized Curcumin in Emulsions and Hydrogel Systems: A Nutritional Strategy for Cardiovascular and Renal Protection in Hypercholesterolemia |
| 9:50–9:55 | Mariam Moalla | Genetic Diagnosis of 46,XY Disorders of Sex Development (DSDs): Insights for Personalized Management |
| 9:55–10:00 | Celeste Moya-Valera | Comprehensive Analysis of Genetic and Environmental Factors Influencing Type 2 Diabetes in the Spanish Population with NGS and the SEQENS Algorithm |
Book of Abstracts
Poster Gallery
Event Awards
To acknowledge the support of the conference's esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to announce that the conference will provide six awards including Best Oral Presentation Awards and Best Poster Awards.
The Awards
Number of Awards Available: 6
The Best Oral Presentation Awards are given to the submission judged to make the most significant oral contribution to the conference.
The Best Poster Awards are given to the submission judged to make the most significant and interesting poster for the conference.
There will be six winners selected for these awards. The winner will receive a certificate and 200 CHF each.
Event Chairs
Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA;
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA
Laboratory for Medical Mass Spectrometry, Biomedicine group, Aalborg University, Aalborg, Denmark
Dr. Allan Stensballe is a prominent figure in the fields of proteomics, systems biology, inflammation, biomarker discovery, and omics data analysis. He is associated with Aalborg University's Department of Health Science. Dr. Stensballe's expertise is deeply rooted in proteomics and the application of proteomics for understanding human disease pathology, especially in the context of precision medicine. He has been pivotal in leading the precision health segment of the Translational Biomarkers for Pain and Precision Medicine research group at Aalborg University in Denmark. This initiative aims to bridge the gap between academic research and small to medium-sized enterprises (SMEs) through technology-driven innovation, particularly in crucial areas that impact global health and wellness.
Department of Pathology, Paracelsus Medical University, Klinikum Nuremberg, Germany
Prof. Dr. Georgia Levidou is a consultant Pathologist at the Department of Pathology, Paracelsus medical university in Nuremberg, Germany. She received her medical degree (MD), PhD and MSc in Biostatistics at the University of Athens, Greece. She has a twenty years’ experience on pathology and research acquired in leading research centers and is an author of more than 87 peer-reviewed articles. Her research interests span both cancer diagnostics, cellular and molecular pathology as well as tumor prognostic and therapeutic biomarkers. Prof. Levidou has a special interest in hematopathology and is currently working especially on the field of thymic epithelial tumors.
Retired Professor of Internal Medicine, Federico II University School of Medicine, Naples, Italy
Serafino Fazio MD was born in Naples (ITALY) on February 5,1950. Master’s degree in Medicine and Surgery at the University Federico II of Naples, School of Medicine on December 21,1974. Specialized in Internal Medicine and in Cardiology. He worked first as university researcher and, later, as associated professor of Internal Medicine, at the University Federico II of Naples, School of medicine from July 1975 to July 2012. Now retired. Author of more than 173 papers published on prestigious Journals. Among them: New England Journal of Medicine, Nature medicine, Annals of Internal Medicine, Circulation, International Journal of Cardiology etc. He was particularly interested in the interaction between hormones and heart, heart failure treatment, metabolic syndrome, nutraceutical substances and, recently, in Covid19 treatment. His h-hindex, according to Google scholar is 49.
Session Chairs
Laboratory for Medical Mass Spectrometry, Biomedicine Group, Aalborg University, Aalborg, Denmark
Department of Pathology, Paracelsus Medical University, Klinikum Nuremberg, Germany
Retired Professor of Internal Medicine, Federico II University School of Medicine, Naples, Italy
Department of Life Sciences, European University Cyprus, Nicosia 2404, Cyprus,
School of Infection and Immunity, University of Glasgow, Glasgow G12 8TA, UK
Servicio de Genética, Hospital Universitario Ramóny Cajal - IRYCIS, Madrid, Spain,
Unit 728, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
HUN-REN-SZTE Neuroscience Research Group, Hungarian Research Network, University of Szeged (HUN-REN-SZTE), Szeged, Hungary
Department of Health Sciences, Center for Translational Research on Autoimmune and Allergic Disease-CAAD, Università del
Piemonte Orientale, 28100 Novara, Italy
School of Pharmacy, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China
Dr. Songwei Tan is an Associate Professor in Pharmaceutics at Tongji School of Pharmacy, Huazhong University of Science and Technology. His research focuses on biomedical polymer materials and novel drug delivery systems. He has led multiple national and local research projects, published over 30 SCI papers (4 ESI highly cited), and holds 3 invention patents. His work aims to advance innovative pharmaceutical formulations for clinical applications.
Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, Caserta, Italy
genetic dyslipidemias; familial hypercholesterolemia; LDL mutations; lipid metabolism; cardiovascular genetics; PCSK9; cardiomyopathies
Event Committee
Prof. Ubaldo Armato, MD
Section of Maxillofacial Surgery & Odontostomatology Dept. Surgery, Dentistry, Paediatrics & Gynaecology Medical School, University of Verona Verona, Veneto, I-37134 Italy
tissue engineering; tissue regeneration; skin; vessels; biomaterials; silk fibroin; exosomes; Alzheimer’s disease; astrocytes; neuroinflammation
uarmato@gmail.com
Prof. Dr. Che-Kun James Shen
1. The PhD Program for Neural Regenerative Medicine, Taipei Medical University, Taipei 115, Taiwan; 2. Institute of Molecular Biology, Academia Sinica, Taipei 115, Taiwan
gene regulation; chromatin; DNA methylation; neurofunction; transcription
ckshen@gate.sinica.edu.tw
Prof. Dr. Celestino Sardu
Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy
clinical cardiology; myocardial infarction; cardiovascular genetics; clinical electrophysiology; molecular cardiology
drsarducele@gmail.com
Prof. Dr. Yan-Ru Lou
University of Helsinki, Finland
endocrinology; stem cell; tissue engineering; regenerative medicine; hepatic differentiation; vitamin D
yan-ru.lou@helsinki.fi
Prof. Dr. Roberto Paganelli
Internal Medicine, UniCamillus, International Medical University in Rome, Italy; (retired) Department of Medicine and Sciences of Aging, University of G. d’Annunzio Chieti and Pescara, Chieti, Italy
immunoglobulins; B and T lymphocyte subpopulations; HIV; cytokines; autoimmunity; allergic diseases; inflammation
roberto.paganelli@unicamillus.org
Dr. Gianluca Santamaria
1. Department of Experimental and Clinical Medicine, University “Magna Graecia” of Catanzaro, Campus “S. Venuta”, Germaneto, Catanzaro, Italy; 2. Department of Medicine I Molecular Cardiology, Klinikum Rechts der Isar—Technical University Munich, Ismaninger Strasse 22, Munich, Germany
identification and characterization of the molecular and cellular pathophysiological mechanisms associated with the development of lung, endometrial, colon, and ovarian cancer; use of induced pluripotent stem cells as a model for the dissection of the molecular mechanisms governing either the maintenance of pluripotency or cellular transitions during cardiogenesis for the study of congenital heart disease; development of analysis pipelines associated with single-cell next-generation sequencing and integration of biological-omic data
santamariagianluca@gmail.com
Dr. Amedeo Amedei
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
microbiota-immunity axis; autoimmunity; cancers; inflammation; T cells; micro and nanoplastic effects on human
amedeo.amedei@unifi.it
Dr. Bernard Lebleu
Laboratory of Pathogen Host Interactions, Biology-Health Department, Montpellier University, Montpellier, France
oligonucleotides-based therapeutics; peptide (cell penetrating peptides)-based delivery vectors; antisense oligonucleotides cellular trafficking
marinaetbernard@lebleu.net
Dr. Andrei Surguchov
Department of Neurology, University of Kansas Medical Center, Kansas City, KS 66160, USA
synuclein; neurodegeneration; Parkinson's disease; caveolin; neurodegenerative diseases; SUP35; SUP45
apsurguchov@yahoo.com
Dr. Cristina Carvalho
Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517, Coimbra, Portugal
Alzheimer’s disease; mitochondrial dysfunction; cell (dys)metabolism; type 2 diabetes
cristina.im.carvalho@gmail.com
Dr. Pedro A. José
Medicine and Physiology/Pharmacology, School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA
hypertension; renal physiology; ion transport; oxidative stress; pharmacogenomics
pjose01@georgetown.edu
Dr. Kevin W.-H. Lo
Department of Medicine, University of Connecticut Health Center, Farmington, CT 06030, USA
drug screening, drug delivery; regenerative engineering; signaling transduction
wlo@uchc.edu
Dr. Donato Liloia
Department of Psychology, University of Turin, Turin, Italy
magnetic resonance imaging; human brain mapping; meta-research; connectomics; brain connectivity; computational neuroscience; Bayesian statistics; fMRI; meta-analysis; clinical trials; DTI; default mode network; Alzheimer’s disease; biological psychiatry; autism; cerebellum; translational neuroimaging
donato.liloia@unito.it
Dr. Yongxiao Wang
Department of Molecular and Cellular Physiology, Albany Meidcal College, Albany, CA, USA
inflammation; reactive oxygen species; cell calcium; ion channels; neurotransmitter receptors; protein kinases
wangy@amc.edu, [no time]
Dr. Michele Ammendola
Department of Health Science, Digestive Surgery Unit, Medical School, University “Magna Graecia”, Viale Europa, Germaneto, 88100 Catanzaro, Italy
surgical oncology; angiogenesis and lymphangiogenesis in gastrointestinal tumor; molecular aspects; traslational reserch in surgery
michele.ammendola@unicz.it
Dr. Andrea Székely
Department of Anesthesia and Intensive Care, Semmelweis University, Budapest, Hungary
transplantation; cardiac anesthesia; psychosocial factors; frailty
andi_szekely@yahoo.com
Dr. Arturo Cesaro
Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, Caserta, Italy
genetic dyslipidemias; familial hypercholesterolemia; LDL mutations; lipid metabolism; cardiovascular genetics; PCSK9; cardiomyopathies
arturo.cesaro@unicampania.it
Dr. Bruno M. Fonseca
UCIBIO – Applied Molecular Biosciences Unit, Laboratory of Biochemistry, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira no. 228, 4050-313 Porto, Portugal
pregnancy pathologies; endometrial receptivity; inflammasome; angiogenesis; inflammation; cannabinoids
brunofonseca@ff.up.pt
Prof. Dr. Patrícia C. Pires
Faculty of Pharmacy, University of Coimbra, Portugal
Biomedicines; Cancer; Drug Delivery; Nanomedicines; Pharmaceuticals
patriciapires93@gmail.com
Dr. Alessandro Genazzani
Gynecological Endocrinology Center, Department of Obstetrics & Gynecology, Università degli Studi di Modena e Reggio Emilia, Modena, Italy
female reproduction; PCOS; menopause; insulin resistance; stress; functional hypothalamic amenorrhea
algen@unimo.it
Dr. Elisa Belluzzi
1. Musculoskeletal Pathology and Oncology Laboratory, Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, 35129 Padova, Italy
inflammation; molecular biology; cell biology; osteoarthritis; cartilage; musculoskeletal diseases; bone cancer; synovium; infrapatellar fat pad; chodrosarcoma
elisa.belluzzi@unipd.it
Keynote Speakers
Department of Health Science, University “Magna Graecia” Medical School, Digestive Surgery Unit, "Renato Dulbecco" Hospital, Viale Europa, Germaneto, 88100 Catanzaro, Italy
Prof. Michele Ammendola is an Associate Professor of General Surgery. Author of many scientific articles published in international journals with international collaborations. Member of International Scientific Societies. His ongoing research interests involve the study of tumor microenvironment, particularly analyzing the role of immune stromal cells in neoangiogenesis of gastrointestinal solid tumors (Study of the mechanisms of remodeling of the tumor microenvironment in colorectal tumors, Principal Investigator in the PRIN 2022 2022CMTZNH project).
President of ASMD Spain (Patients Association),
Board member of FEDER (Spanish Federation of Rare Diseases),
Board member of Eurordis (Rare Diseases Europe)
Cedars-Sinai Medical Center & UCLA, Los Angeles, CA, USA
Tumor-targeted nanodrug inhibiting glioblastoma-enriched laminin-411 stimulates brain immune system and suppresses tumor growth.
Professor Ljubimov is Director of the Division of Applied Cell Biology and Physiology, Department of Biomedical Sciences, and Director of the Board of Governors Regenerative Medicine Institute Eye Program at Cedars-Sinai Medical Center, and Professor of Medicine at UCLA. He is an internationally known cancer and ocular diabetes researcher. He authored over 140 publications and is on 15 Editorial Boards. He is Gold Fellow of the Association for Research in Vision and Ophthalmology and Overseas Fellow of the Royal Society of Medicine.
Invited Speakers
Department of Health Sciences, Interdisciplinary Research Center of Autoimmune Diseases—IRCAD, University of Eastern Piedmont, 28100 Novara, Italy
From data to diagnosis: biomarker discovery in amyotrophic lateral sclerosis
Davide Raineri is an assistant professor since March 2023. He obtained a PhD in medical sciences and biotechnology in 2020. During his PhD, he studied the interaction of osteopontin and its new receptor (ICOSL). He currently manages the various projects involving the use of the instrumentation present within the new generation cytometry facility, for which he is the referent, comprising the FACSymphony A5 flow cytometer, the cell sorter FACSAria FUSION, the mass cytometer and also the BD RHAPSODY.
Program of Immunology and Immunotherapy, CIMA-Universidad de Navarra, Pamplona, Spain.,
Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.,
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
A comprehensive analysis of Fibromyalgia and the role of the endogenous opioid system
Mario García Domínguez holds a degree in Biology and a PhD from the University of Oviedo (Spain). He’s currently a researcher in the Department of Immunology and Immunotherapy at the Medical Research Center of the University of Navarra and simultaneously serves as a assistant professor at Universidad Antonio de Nebrija. He has presented his research at three international conferences, with two presentations in poster format and one as an oral presentation.
Department of Chemistry, Chemical and Life sciences, Wuhan University of Technology, Wuhan 430070, China
Reshaping tumor microenvironment through polymeric nanoparticles featured with CRISPRi system and epigenetic inhibitor
Huan Deng is an associated research fellow of pharmaceutics, Wuhan university of technology (WHUT), China. Her research interests focus on developing novel drug delivery system for cancer immunotherapy, including the delivery of CRISPR-Cas9 system, small molecular and epigenetic inhibitors. She has published 11 high-level papers as first or corresponding author, and is the lead of several projects, including the National Natural Science Youth Fundation.
School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China
Non-canonical energy expenditure in adipocytes: mechanisms and intervention strategies.
Dr. Hui obtained her B.Sc. in Biotechnology from Shanghai Jiao Tong University and completed her Ph.D. study in Shanghai Institute of Biological Sciences, Chinese Academy of Sciences (SIBS, CAS). She pursued her postdoctoral training at Department of Medicine, the University of Hong Kong and later took up a post as Research Assistant Professor at the same department. In 2021, she joined the School of Biomedical Sciences, the Chinese University of Hong Kong as Assistant Professor. The goal of Prof. Hui’s lab is to understand the molecular basis of adipose tissue remodelling and its physiological relevance in obesity and cardio-metabolic diseases. Her lab seeks to develop biomedicine that can educate the dysfunctional adipose tissue to a metabolically beneficial organ. She is the principal investigator of research grants including General Research fund (GRF), Health and Medical Research Fund (HMRF), NSFC-RGC, and NSFC (Young Excellent Scientist).
"THE PROTECTIVE EFFECT OF SIMVASTATIN ON DOXORUBICIN-INDUCED SHORT-TERM CARDIOTOXICITY"
Ada Popolo is an Associate Professor of Pharmacology at the University of Salerno, Department of Pharmacy, since 2020. Her research focuses on the mechanisms of chemotherapeutic drug-induced cardiotoxicity, the identification of novel therapeutic targets, and the evaluation of new drugs. She has authored 57 publications in peer-reviewed journals, contributed to 3 book chapters, and actively participates in national and international scientific conferences.
Associate Professor , Department of Cardiology , The University of Texas MD Anderosn Cancer Center, Houston, Texas, 77030, USA
Mechanosensitive Hippo-YAP Pathway: A Key Regulator in Atherosclerosis Development
"Dr. Kotla is an Assistant Professor in the Department of Cardiology at The University of Texas MD Anderson Cancer Center. He holds a Ph.D. in Biotechnology from Indian Veterinary Research Institute, Bangalore India, where he focused on foot-and-mouth disease virus (FMDV) biology, including vaccine efficacy and immune responses. Dr. Kotla’s post-doctoral work at the University of Tennessee Health Science Center centered on redox regulation in vascular inflammation and atherosclerosis, and he was later promoted to Research Instructor. In 2017, he joined MD Anderson, where his research focuses on understanding cardiotoxicity associated with cancer therapies. Using transgenic and knockout mouse models, his work integrates molecular biology, cell-based assays, metabolism, and mitochondrial biology to uncover cardiovascular damage in cancer patients and develop strategies to reduce this toxicity."
Recent advances in nanomedicine for skin cancer immunotherapy – a focus on nanosystems, drug repurposing and co-loading for synergistic effects
Prof. Dr. Patrícia C. Pires is an Invited Professor at the Faculty of Pharmacy, University of Coimbra. She holds a PhD and a Master’s degree in Pharmaceutical Sciences from the University of Beira Interior. Her research interests include drug delivery, biomedicines, and innovative pharmaceutical formulations, with a focus on improving therapeutic outcomes. She actively contributes to the scientific community through teaching, research, and international collaborations.
Sessions
S2. Immunotherapy and Adverse Effects
S3. Tumor Microenvironment
S4. Immune System, Tumor Immunology and Autoimmune Disease
S5. Biomedicine in Cardiovascular Diseases
S6. Diabetes, Obesity and Metabolic Diseases
S7. Gene Therapy and Gene Editing
S8. Rare Diseases
S9. Molecular Mechanisms of Neurodegeneration
Registration
When registering, please register with your academic email address, as this will accelerate the registration process. If you are registering several people under the same registration, please do not use the same email address for each person, but their individual university email addresses. Thank you for understanding.
The number of participants is limited; once the number of registrations reaches the maximum number of participants, another registration will be cancelled.
Finally, only registered authors will be able to apply for the Conference Awards.
Instructions for Authors
The 3rd International Electronic Conference on Biomedicines will accept abstracts only. The accepted abstracts will be available online on Sciforum.net during and after the conference.
1. Deadline for abstract submission: 10 February 2025 .
2. Abstract Acceptance Notification: 10 March 2025. You will be notified of the acceptance of an oral/poster presentation in a separate email.
Abstract submissions should be completed online by registering with www.sciforum.net and using the "New Submission" function once logged into the system. No physical template is necessary.
1. The structure abstract should include the introduction, methods, results, and conclusions sections of about 250–300 words in length.
2. All accepted abstracts will be published in the conference report of The 3rd International Electronic Conference on Biomedicines in Medical Sciences Forum Journal (ISSN 2673-9992); if you wish to publish an extended proceeding paper (5-9 pages), please submit it to the same journal after the conference.
3. All abstracts should be submitted and presented in clear, publication-ready English with accurate grammar and spelling.
4. You may submit multiple abstracts. However, only one abstract will be selected for oral presentation.
5. All abstracts accepted for presentation will be collected in a book of abstracts, which will be published on the website after the conference.
Detailed Requirements:
1. The submitting author must ensure that all co-authors are aware of the contents of the abstract.
2. Please select only one presenter for each submission. If you would like to change the presenter after submission, please email us accordingly.
Note: We only accept live presentations.
The slot for the oral presentation is 15 mins. We advise that your presentation lasts for a maximum of 12 mins, leaving at least 3 mins for the Q&A session. Authors are encouraged to prepare a presentation in PowerPoint or similar software.
Selected submissions will have the opportunity to be presented orally, with each presentation lasting 3–5 minutes, during the Flash Poster Session scheduled for 15 May 2025, from 9:00 to 10:00 AM CEST.
a. Should include the title, authors, contact details and main research findings, as well as tables, figures and graphs where necessary.
b. Size in pixel: 1080 width x 1536 height–portrait orientation.
c. Size in cm: 38,1 width x 54,2 height–portrait orientation.
d. Font size: ≥16.
You can use our free template to create your poster. The poster template can be downloaded here.
Poster Gallery
All posters, including those not selected for the Flash Poster Session, are invited to be submitted for permanent online exhibition in the Poster Gallery on the conference website. Please note that this section is for display purposes only; no presentation time slot will be allocated. However, all displayed posters will still have a chance to be considered for the Best Poster Award, which includes a certificate and a prize of 200 CHF.
Authors who wish to submit a poster are invited to send it to the conference email at ecb@mdpi.com. We will reach out to you closer to the dates of the conference with more information.
It is the authors' responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state "The authors declare no conflicts of interest." This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Any financial support for the study must be fully disclosed in the "Acknowledgments" section.
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe authors should retain the copyright to their scholarly works. Hence, by submitting an abstract to this conference, you retain the copyright to the work, but you grant MDPI the non-exclusive right to publish this abstract online on the Sciforum.net platform. This means you can easily submit your full paper (with the abstract) to any scientific journal at a later stage and transfer the copyright to its publisher if required.
Publication Opportunities
1. Biomedicines Journal Publication
Participants in this conference are cordially invited to contribute a full manuscript to the conference's Special Issue 'Selected Papers in the 3rd International Electronic Conference on Biomedicines (ECB 2025)', published in Biomedicines (ISSN: 2227-9059, Impact Factor 3.9), with a 20% discount on the publication fee. For more information, please visit the website here.
Please note that no other discounts are applicable. All submitted papers will undergo MDPI’s standard peer-review process. Acceptance of the abstract does not guarantee acceptance of the manuscript. Additionally, the accepted abstract should be cited and noted on the first page of the paper.
2. Proceeding Paper Publication
You are welcome to submit a proceeding paper (5-9 pages) to Medical Sciences Forum Journal (ISSN 2673-9992) after the conference. Publication of the proceedings will be free of charge. Authors are asked to disclose that it is a proceeding paper of the ECB 2025 conference paper in their cover letter. Please submit your manuscript from 15 May to 31 June 2025. Carefully read the rules outlined in the 'Instructions for Authors' on the journal’s website and ensure that your submission adheres to these guidelines.
Manuscripts for the proceedings issue must be formatted as follows:
-
Title.
-
Full author names.
-
Affiliations (including full postal address) and authors' e-mail addresses.
-
Abstract.
-
Keywords.
-
Introduction.
-
Methods.
-
Results and Discussion.
-
Conclusions.
-
Acknowledgements.
-
References.
Sponsors and Partners
Organizers
Co-organizers
Media Partners
Conference Secretariat
Ms. Yachne Yu
Ms. Alethea Liu
Ms. Suriwipa Chuachaina
Email: ecb@mdpi.com
For inquiries regarding submissions and sponsorship opportunities, please feel free to contact us.
